ClinicalTrials.gg
CompletedNCT00601458Updated Apr 10, 2015Results posted

Bunionectomy Study (0000-063)

A Phase 1 interventional study of pregabalin and naproxen sodium in Acute Pain, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

We are interested in whether bunionectomy can be used as a model to study the treatment of acute pain. It has been used to study the effect of Non-Steroidal Anti-inflammatory (NSAIDS) medications (such as ibuprofen) and other pain relieving drugs. We are interested to know if this model is useful to study other drugs for the treatment of acute pain. The other drugs being tested in this study are pregabalin and naproxen sodium. These drugs are approved for use by the Food and Drug Administration (FDA). This study is designed to test whether these two drugs are effective in treating pain after a bunionectomy.

02

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Primary, unilateral, first metatarsal bunionectomy with osteotomy
03

In context

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

This study's enrollment of 100 is above the median of 86 across 905 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is a man or woman between 18 and 65 years of age
  • For Women of : woman who is currently not pregnant not nursing and who is willing to use a medically acceptable method of from the time after the screening visit until completion of the follow-up visit
  • Patient is scheduled to have a bunionectomy
  • Patient must be willing to stay at the study site throughout the 48-hour observation period following surgery and is willing to complete a 2-week follow up
  • Patient is capable of operating a Patient Controlled Analgesia device

Exclusion criteria

Exclusion Criteria:

  • Patient is being treated for a disease and has not been on a stable dose of medication for at least 2 weeks prior to surgery
  • Patient has used or intends to use any of the medications that are prohibited by the protocol, which could interfere with the evaluation of the study drugs
  • Patient has an estimated of \< or = 60 mL per min
  • Patient has a history of drug abuse or dependence, or patient has a positive urine drug screen
  • Patient has a condition that prevents clear communication concerning pain perception (such as diabetic neuropathy, peripheral neuropathy, etc.)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Arm 1: Pregabalin 300 mg

    Drug: pregabalin

  • Active comparator
    Arm 2: naproxen sodium 550 mg

    Drug: naproxen sodium

  • Placebo comparator
    Arm 3: Placebo

    Drug: Comparator: Placebo

Interventions

  • Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.

  • Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.

    Also known as: naproxen

  • DrugComparator: Placebo

    Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.

06

What researchers measure

Primary outcomes

  1. Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery

    Total dose (amount) of hydromorphone via patient controlled analgesic (PCA) pump required in the 24 hours post-surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.

    Time frame: First 24 hours following surgery

Secondary outcomes

  1. Time to First Request of PCA Hydromorphone

    Time (in hours) to first patient controlled analgesic (PCA) pump use after surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.

    Time frame: First 24 hours following surgery

07

Results

Posted Apr 8, 2010

Participant flow

First Patient Entered: 25 July 2007 Last Patient Last Visit: 28 January 2008 1 site

Participant flow — Overall Study
MilestonePregabalin 300 mgNaproxen Sodium 550 mgPlacebo
Started363430
Completed322928
Not completed452
Withdrew: Dosing error100
Withdrew: Incomplete data020
Withdrew: Protocol violation321
Withdrew: Early termination011

Outcome measures

PrimaryTotal Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery

Total dose (amount) of hydromorphone via patient controlled analgesic (PCA) pump required in the 24 hours post-surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.

Time frame:
First 24 hours following surgery
Reported as:
Geometric mean · milligrams
Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery
milligramsPregabalin 300 mgNaproxen Sodium 550 mgPlacebo
Total Patient Controlled Analgesic (PCA) Hydromorphone Consumption Over the 24 Hours Post-surgery2.94 (2.00 to 5.35)2.07 (0.80 to 4.60)5.96 (4.50 to 7.70)
Statistical analysis
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.005 (1-sided alpha = 0.045 Hochberg closed testing procedure) · Mean difference (final values): -50.7 · 97.8% CI -73.6 to -8.0The natural log scale treatment difference (pregabalin - placebo) and 97.8% CI for the treatment difference were exponentiated and reported as a percentage reduction in 24-h cumulative hydromorphone consumption.
  • Naproxen Sodium 550 mg vs Placebo · ANOVA · p = 0.0001 (1-sided alpha = 0.045 Hochberg closed testing procedure) · Mean difference (final values): -65.4 · 97.8% CI -81.7 to -34.6The natural log scale treatment difference (naproxen - placebo) and 97.8% CI for the treatment difference were exponentiated and reported as a percentage reduction in 24-h cumulative hydromorphone consumption.
SecondaryTime to First Request of PCA Hydromorphone

Time (in hours) to first patient controlled analgesic (PCA) pump use after surgery in each of the treatment arms: placebo, pregabalin 300 mg or naproxen 550 mg.

Time frame:
First 24 hours following surgery
Reported as:
Median · Hours
Time to First Request of PCA Hydromorphone
HoursPregabalin 300 mgNaproxen Sodium 550 mgPlacebo
Time to First Request of PCA Hydromorphone7.3 (5.8 to 9.4)9.1 (7.1 to 13.6)5.8 (5.1 to 7.4)
Statistical analysis
  • Pregabalin 300 mg vs Placebo · Log Rank · p = 0.004 (1-sided alpha = 0.045 Hochberg closed testing procedure) · Median difference (final values): 1.46 · 95% CI 0.183 to 2.95Hodges-Lehmann procedure was used to obtain an estimate of the difference in medians and an exact CI for the difference in medians
  • Naproxen Sodium 550 mg vs Placebo · Log Rank · p = <0.001 (1-sided alpha = 0.045 Hochberg closed testing procedure) · Median difference (final values): 3.70 · 95% CI 1.77 to 6.72Hodges-Lehmann procedure was used to obtain an estimate of the difference in medians and an exact CI for the difference in medians

Adverse events

Collected over AEs were collected from the time the subject signed consent until 14 days following the last dose of study mediciation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 300 mg—0/36 (0%)26/36 (72.2%)
Naproxen Sodium 550 mg—0/34 (0%)19/34 (55.9%)
Placebo—0/30 (0%)25/30 (83.3%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPregabalin 300 mgNaproxen Sodium 550 mgPlacebo
NauseaGastrointestinal disorders16/3614/3421/30
VomitingGastrointestinal disorders7/369/3418/30
HeadacheNervous system disorders8/361/344/30
DizzinessNervous system disorders6/365/343/30
PruritusSkin and subcutaneous tissue disorders1/365/345/30
HyperhidrosisSkin and subcutaneous tissue disorders0/361/344/30
Oxygen Saturation DecreasedInvestigations2/360/343/30
Pharyngolaryngeal PainRespiratory, thoracic and mediastinal disorders0/360/342/30
ConstipationGastrointestinal disorders2/362/341/30
PainGeneral disorders0/362/340/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pregabalin 300 mgNaproxen Sodium 550 mgPlaceboTotal
Mean40.3 ± 14.140.6 ± 13.538.8 ± 11.639.9 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 300 mgNaproxen Sodium 550 mgPlaceboTotal
Female27232373
Male56516
Body Weight
Body Weight(Kilograms)Pregabalin 300 mgNaproxen Sodium 550 mgPlaceboTotal
Mean72.3 ± 18.176.7 ± 17.277.2 ± 16.975.3 ± 17.4
Lidocaine Use
Lidocaine Use(Milliliters)Pregabalin 300 mgNaproxen Sodium 550 mgPlaceboTotal
Mean15.0 ± 2.315.9 ± 2.714.6 ± 1.615.2 ± 2.2
Propofol Use
Propofol Use(Milligrams)Pregabalin 300 mgNaproxen Sodium 550 mgPlaceboTotal
Mean348.4 ± 132.9364.5 ± 122.8353.9 ± 105.8355.4 ± 121.1
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wang H, Gargano C, Lukac S, Jackson A, Beals C, Smiley P, Drexel M, Ruddy M, Herman G, Johnson-Levonas AO, Medve R, Webster L, Reicin A. An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics. Adv Ther. 2010 Dec;27(12):963-80. doi: 10.1007/s12325-010-0084-8. Epub 2010 Nov 3. PubMed 21052881 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2008
First posted
Jan 28, 2008
Start
Jul 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Apr 8, 2010
Last update
Apr 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00601458
Responsible party
Sponsor
First posted
Jan 28, 2008
Start date
Jul 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Apr 8, 2010
Last update
Apr 10, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Naproxen

Start the discussion